A Phase 3 Study of the Safety and Efficacy of Tedizolid Phosphate in Patients <12 Years of Age With Acute Bacterial Skin and Skin Structure Infections
The results of this study provide evidence to support the use of tedizolid phosphate to treat ABSSSI caused by Gram-positive pathogens in pediatric patients from 28 days to <12 years of age.
Authors
- Melissa A. Boddicker (ORCID: https://orcid.org/0000-0002-5944-1738)
- Sandra Koseoglu (ORCID: https://orcid.org/0000-0002-2209-5288)
- O. D. Fofanov (ORCID: https://orcid.org/0000-0003-1437-4161)
- Lizbeth Romero
- Natalya Broyde (ORCID: https://orcid.org/0009-0006-1512-2838)
- Mario Melgar Toledo
- Rosie Mngqibisa (ORCID: https://orcid.org/0000-0002-6540-5733)
- Michael Stevens (ORCID: https://orcid.org/0009-0009-2152-6734)
- Carlos Grazioso
- P.S. Sears
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Ivano-Frankivsk National Medical University (UA)
- King Edward VIII Hospital (ZA)
Publication Details
- Journal
- The Pediatric Infectious Disease Journal
- Published
- 2025-04-14
- DOI
- https://doi.org/10.1097/inf.0000000000004807
- Citations
- 4
- Primary Topic
- Antimicrobial Resistance in Staphylococcus
- Type
- article
- Field-Weighted Citation Impact
- 5.58